PMID- 27005447
OWN - NLM
STAT- MEDLINE
DCOM- 20171218
LR  - 20180302
IS  - 1879-3061 (Electronic)
IS  - 1043-2760 (Linking)
VI  - 27
IP  - 5
DP  - 2016 May
TI  - Unraveling the Effects of PPARbeta/delta on Insulin Resistance and Cardiovascular 
      Disease.
PG  - 319-334
LID - S1043-2760(16)00034-5 [pii]
LID - 10.1016/j.tem.2016.02.008 [doi]
AB  - Insulin resistance precedes dyslipidemia and type 2 diabetes mellitus (T2DM) 
      development. Preclinical evidence suggests that peroxisome proliferator-activated 
      receptor (PPAR) beta/delta activators may prevent and treat obesity-induced insulin 
      resistance and T2DM, while clinical trials highlight their potential utility in 
      dyslipidemia. This review summarizes recent mechanistic insights into the 
      antidiabetic effects of PPARbeta/delta activators, including their anti-inflammatory 
      actions, their ability to inhibit endoplasmic reticulum (ER) stress and hepatic 
      lipogenesis, and to improve atherogenesis and insulin sensitivity, as well as 
      their capacity to activate pathways that are also stimulated by exercise. 
      Findings from clinical trials are also examined. Dissecting the effects of 
      PPARbeta/delta ligands on insulin sensitivity and atherogenesis may provide a basis for 
      the development of therapies for the prevention and treatment of T2DM and 
      cardiovascular disease (CVD).
CI  - Copyright (c) 2016 Elsevier Ltd. All rights reserved.
FAU - Vazquez-Carrera, Manuel
AU  - Vazquez-Carrera M
AD  - Department of Pharmacology and Therapeutic Chemistry, Faculty of Pharmacy, 
      University of Barcelona, Institute of Biomedicine of the University of Barcelona 
      (IBUB), Pediatric Research Institute, Hospital Sant Joan de Deu, Barcelona, 
      Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic 
      Diseases (CIBERDEM)-Instituto de Salud Carlos III, Diagonal 643, 08028 Barcelona, 
      Spain. Electronic address: mvazquezcarrera@ub.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160320
PL  - United States
TA  - Trends Endocrinol Metab
JT  - Trends in endocrinology and metabolism: TEM
JID - 9001516
RN  - 0 (PPAR delta)
RN  - 0 (PPAR-beta)
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/genetics/*metabolism
MH  - Humans
MH  - Inflammation/genetics/metabolism
MH  - Insulin Resistance/genetics/*physiology
MH  - PPAR delta/*metabolism
MH  - PPAR-beta/*metabolism
OTO - NOTNLM
OT  - PPARbeta/delta
OT  - inflammation
OT  - insulin resistance
OT  - type 2 diabetes mellitus
EDAT- 2016/03/24 06:00
MHDA- 2017/12/19 06:00
CRDT- 2016/03/24 06:00
PHST- 2016/01/22 00:00 [received]
PHST- 2016/02/16 00:00 [revised]
PHST- 2016/02/25 00:00 [accepted]
PHST- 2016/03/24 06:00 [entrez]
PHST- 2016/03/24 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
AID - S1043-2760(16)00034-5 [pii]
AID - 10.1016/j.tem.2016.02.008 [doi]
PST - ppublish
SO  - Trends Endocrinol Metab. 2016 May;27(5):319-334. doi: 10.1016/j.tem.2016.02.008. 
      Epub 2016 Mar 20.